Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | AGER | Q15109 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28241780 | 0.90 | MAPT (0.50) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL28428672 | 0.87 | KDM4E (0.61) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL6915981 | 0.86 | KDM4E (0.56) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL4069169 | 0.86 | MAPT (0.45) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL29559479 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL519094 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL311087 | 0.81 | KDM4E (0.71) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL9944385 | 0.80 | ELANE (0.46) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL4060677 | 0.80 | KMT2A (0.47) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL27869506 | 0.80 | ALDH1A1 (0.69) | KDM4EALDH1A1MAPTL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111004171-A | Novel synthesis method of 3-fluoropyridine-2-methanol | 南开大学 | 2020-04-14 | — | — | CN | claimed |
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111004171-A | Novel synthesis method of 3-fluoropyridine-2-methanol | 南开大学 | 2020-04-14 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-1326865-B1 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| CN-1726212-A | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES INC (US) | 2006-01-25 | — | — | CN | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1558613-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | CCNI, INTS6, CCNE1 | KDM4E 1925/4885ALDH1A1 1113/4885MAPT 4600/4885 |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | KDM4E 2029/4885ALDH1A1 2955/4885MAPT 1418/4885 |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | KDM4E 1139/4885ALDH1A1 2541/4885MAPT 4371/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | KDM4E 1139/4885ALDH1A1 2541/4885MAPT 4371/4885 |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | KDM4E 1594/4885ALDH1A1 1902/4885MAPT 4602/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | KDM4E 1618/4885ALDH1A1 2788/4885MAPT 2025/4885 |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | KDM4E 647/4885ALDH1A1 333/4885MAPT 4490/4885 |
| US-20090306054-A1 | INTEGRASE INHIBITORS | TYMP, POLR2E, CCNI | KDM4E 960/4885ALDH1A1 1220/4885MAPT 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.